China-based Viva Biotech recently held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform to the industry.
During the event, Dr Yue Qian, Executive Director of the AIDD/CADD Platform at Viva Biotech, delivered an in-depth overview of the unique strengths of the AIDD platform, its disruptive innovations across the drug discovery process, and its three core modules—V-Scepter, V-Orb, and V-Mantle.
Through a series of case studies, Dr Qian showcased how Viva's AIDD platform acts as a transformative "enchantment" for drug R&D, offering an intelligent, efficient, and integrated approach to accelerate the discovery of novel therapeutics.
For the first time, Viva Biotech officially launches its own AI-Driven Drug Discovery platform, powered by three core modules like the three hallows. V-Scepter resembles the elder wand that empowers the computational modeling with fundamental rules. V-Orb reveals the underlying mechanisms of the biological system. And V-Mantle is the invisible cloak weaved at Viva to explore the hidden space of drug discovery with the help of generative AI models.
Artificial intelligence (AI) has rapidly evolved from academic theory into a transformative force in pharmaceutical R&D. From early QSAR models to neural networks, and now to AlphaFold3, AI has progressively unlocked deeper biological insights. By integrating structure prediction, molecular modeling, and data-driven discovery, AI is becoming the virtual wand of modern drug discovery, turning scientific imagination into real-world therapeutics.
